InsidersTradesSigma
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
Explore the complete record of transactions filed by Oki Mark K, 首席财务官. Director active across 2 companies, notably Aytu Biopharma, INC. Aggregated, 5 disclosures have been published. Breakdown: 2 buys · 0 sell. Total volume traded: €47k. Activity tracked since 17 January 2022. The latest transaction was disclosed on 18 September 2025 (Levée d'options). Regulator: SEC (Form 4). The full history is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 条申报中的 5 条
Oki Mark K is the Chief Financial Officer of AYTU BIOPHARMA, INC. He is responsible for the financial management of the company, including budgeting, financial analysis, and investment management. His expertise is essential in ensuring the financial viability and growth of the company in the biopharmaceutical sector. He plays a key role in financial strategy and decision-making.